2 Stocks That Could Realistically Double by 2030 Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead.
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (
NYSE: GS ) has released its highly anticipated 2026 Global M&A Outlook, titled "Think Big, Build Bigger," predicting a massive 15% increase in merger and acquisition deal
2 Healthcare Stocks to Buy Before They Get Bought Out Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
